Malobika Bhattacharya1, Neha Joshi, Sangita Yadav. 1. Department of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi, 110002, India, drmalvika_b@rediffmail.com.
Abstract
OBJECTIVES: To evaluate whether promethazine and dextromethorphan reduce nocturnal cough and improve sleep quality in children aged 1-12 y with upper respiratory tract infection (URI). METHODS: This randomised double-blinded placebo-controlled trial was conducted in Pediatric outpatient department of Lok Nayak Hospital, Delhi. After randomization into promethazine, dextromethorphan and placebo groups, parental assessment of 120 children with URI for nocturnal cough severity (child), post-tussive vomiting (child) and sleep quality (child and parent) on the night before enrolment and after 3 d of assigned medication was measured using an internally validated indigenously prepared ordinal scale. RESULTS: Entire cohort improved in all the study parameters after 3 d. However, no superior benefit was noted when individual parameters were compared in the promethazine and dextromethorphan groups with the placebo group. Adverse effects were more frequent in the dextromethorphan and promethazine groups although the difference was not statistically significant. CONCLUSIONS:Nocturnal cough in URI is self-resolving and dextromethorphan and promethazine prescribed for the same are not superior to placebo.
RCT Entities:
OBJECTIVES: To evaluate whether promethazine and dextromethorphan reduce nocturnal cough and improve sleep quality in children aged 1-12 y with upper respiratory tract infection (URI). METHODS: This randomised double-blinded placebo-controlled trial was conducted in Pediatric outpatient department of Lok Nayak Hospital, Delhi. After randomization into promethazine, dextromethorphan and placebo groups, parental assessment of 120 children with URI for nocturnal cough severity (child), post-tussive vomiting (child) and sleep quality (child and parent) on the night before enrolment and after 3 d of assigned medication was measured using an internally validated indigenously prepared ordinal scale. RESULTS: Entire cohort improved in all the study parameters after 3 d. However, no superior benefit was noted when individual parameters were compared in the promethazine and dextromethorphan groups with the placebo group. Adverse effects were more frequent in the dextromethorphan and promethazine groups although the difference was not statistically significant. CONCLUSIONS:Nocturnal cough in URI is self-resolving and dextromethorphan and promethazine prescribed for the same are not superior to placebo.
Authors: N Hutton; M H Wilson; E D Mellits; R Baumgardner; L S Wissow; C Bonuccelli; N A Holtzman; C DeAngelis Journal: J Pediatr Date: 1991-01 Impact factor: 4.406
Authors: Louis-Philippe Boulet; Remy R Coeytaux; Douglas C McCrory; Cynthia T French; Anne B Chang; Surinder S Birring; Jaclyn Smith; Rebecca L Diekemper; Bruce Rubin; Richard S Irwin Journal: Chest Date: 2015-03 Impact factor: 9.410
Authors: Samuel H F Lam; James Homme; Jahn Avarello; Alan Heins; Denis Pauze; Sharon Mace; Ann Dietrich; Michael Stoner; Corrie E Chumpitazi; Mohsen Saidinejad Journal: J Am Coll Emerg Physicians Open Date: 2021-06-18